All In MedTech

Device Trial Radar · NCT05027984

Interventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria at OCT in Patients With ACS

An Interventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria Identified by Optical Coherence Tomography in Patients With Acute Coronary Syndrome (the INTER-CLIMA Trial)

Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 1,425 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

1,425

Actual

Start

Jun 30, 2021

Primary completion

Jan 31, 2027

Study completion Mar 31, 2030

Sponsor

Lead sponsor
Centro per la Lotta Contro l'Infarto - Fondazione OnlusAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Abbott Medical Devices
First posted
Aug 31, 2021

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The INTERCLIMA (Interventional Strategy for Non-culprit Lesions With Major Vulnerability Criteria Identified by Optical Coherence Tomography in Patients With Acute Coronary Syndrome) is a multi-center, prospective, randomized trial of optical coherence tomography (OCT)-based versus physiology-based (i.e. fractional flow reserve\[FFR\]/instantaneous Wave-Free Ratio\[iFR\]/resting full-cycle ratio\[RFR\]) treatment of intermediate (40-70% diameter stenosis), non-culprit coronary lesions in acute coronary syndrome (ACS) patients undergoing coronary angiography. About 1420 patients with ACS will be randomized into the study at approximately 40 sites worldwide.

Conditions

  • Coronary Artery Disease
  • Coronary Disease
  • Ischemic Heart Disease

Interventions

  • Optical coherence tomographyDevice

    OCT images will be acquired by means of the FD C7 XR system or the OPTIS system (both St. Jude Medical, St. Paul, MN, USA) with a non-occlusive technique.(33) The acquired OCT coronary images will be analyzed on-line using a proprietary OCT console (St Jude Medical, Inc., USA). Definitions and cut-offs for OCT vulnerability parameters derived from available consensus documents and from main IVUS/OCT studies.

  • iFR/FFR/RFRDevice

    The iFR and FFR measurements will be obtained using a coronary-pressure guidewire (Pressure Wire / Certus or Aeris for FFR assessment and PressureWire™ X Guidewire/QUANTIEM™ for the RFR assessment by Abbott Vascular, Abbott Park, Illinois, U.S.A; Comet by Boston Scientific, Marlborough, MA, USA), OptoWire by Opsens, Quebec, Canada, or Verrata by Philips, San Diego, CA, USA.).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of patients with cardiac death or non-fatal spontaneous target-vessel myocardial infarctionTime frame: 3 years

Locations

34 sites in 4 countries. Site status is shown where the registry gives one.

  • University Hospital of Patras

    Pátrai, AX, Greece

  • Federico II di Napoli

    Naples, Italy

  • Ospedale C. e G. Mazzoni

    Ascoli Piceno, AP, Italy

31 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.